Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
Affiliation
Department of Dermatology, University of Kiel, Germany. kckaehler@yahoo.deIssue Date
2009-10
Metadata
Show full item recordAbstract
Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is an immunoregulatory molecule expressed by activated T cells and resting CD4+CD25 T cells. In patients with advanced melanoma, anti-CTLA-4 antibody therapy achieves cancer regression in 15% of patients. Treatment may be associated with grade III/IV autoimmune manifestations that included dermatitis, enterocolitis, hepatitis, uveitis, and rarely hypophysitis. Many of these toxicities require and respond to brief courses of high-dose corticosteroids. We report on a case of autoimmune hypophysitis with severe clinical symptoms that resolved rapidly after treatment with steroids. It is important to consider both autoimmune hypophysitis and brain metastasis in the differential diagnosis of melanoma patients receiving CTLA-4 blockade who present this constellation of symptoms.Citation
Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. 2009, 19 (5):333-4 Melanoma Res.Journal
Melanoma ResearchDOI
10.1097/CMR.0b013e32832e0bffPubMed ID
19512947Type
ArticleLanguage
enISSN
1473-5636ae974a485f413a2113503eed53cd6c53
10.1097/CMR.0b013e32832e0bff